SEngine Precision Medicine Licenses Hutch Cancer Drug Screening Assay

Jul 06, 2017

|

NEW YORK (GenomeWeb) – SEngine Precision Medicine has inked an exclusive licensing agreement with the Fred Hutchinson Cancer Research Center to market a diagnostic test designed to aid in the personalization of cancer treatments.

The assay, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

Holden Thorp to Take Over at Science

Holden Thorp is to be the new editor-in-chief of Science and its related journals.

Fewer Fish in the River

A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.

Ancient DNA Lab Head Suspended During Workplace Culture Review

Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.

PNAS Studies Describe Adipocyte Subtypes, Plant Expressome Analysis, More

In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.

Featured White Papers

10 Tips to Scale Your Diagnostics Business and Grow Your Test Portfolio Globally

Build vs. Buy? 6 Questions to Consider When Investigating Clinical Diagnostics Informatics Solutions

BlueBee Data Security & Compliance

Whole Genome Sequencing of Microbial Communities for Scaling Microbiome and Metagenomic Studies

Aug

22

Featured Webinar

Biobanks and the Rise of Precision Medicine: Lessons from the Estonian Biobank

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Sep

18

Featured Webinar

Highly Sensitive Structural Variant Detection for Medical Genetics: A Comparison to the Standard of Care

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Menu